PF974

PreclinicalSmall molecule

YYale University

PF974 is one of 10 small molecule programs targeting Psychiatric Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psychiatric DisorderActive, not recruiting

Psychiatric DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Psychiatric Disorder

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

1 2

Lexapro

AbbVie

Approved

1 3

Chantix

PPrism Pharmaceuticals

Approved

1 4

Pitocin

Suboxone

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 7

Dayvigo

Eisai

Preclinical

1 8

Skyclarys

Biogen

Preclinical

—9

Conservative Treatment

PPeking University Third Hospital

Preclinical

1 10

PF974

YYale University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Not yet recruiting

Psychiatric Disorder

NCT07488819

Clinical

Trials by Indication[1]

Psychiatric Disorder1 trial

Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974

Not yet recruiting·YYale University··NCT07488819·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PF974. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF974 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF974. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYale University

PF974

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Psychiatric Disorder1 trial

References

Drug Info

Quick Facts

Related News